Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

Nuclear Medicine and Molecular Imaging

Volumn 47, Issue 1, 2013, Pages 44-51

  Jin, Soyoung ^a   Oh, Minyoung ^a   Oh, Seung Jun ^a   Oh, Jungsu S ^a   Lee, Sang Ju ^a   Chung, Sun Ju ^a   Lee, Chong Sik ^a   Kim, Jae Seung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Atypical parkinsonism; Dual phase; F 18 FP CIT; PET; Positron emission tomography

Indexed keywords

DOPAMINE TRANSPORTER; FLUORINE FP CIT F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ESSENTIAL TREMOR; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84874222032     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-012-0182-4     Document Type: Article

References (41)

1. Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol. 1993; 60: 595-9.
2. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984; 16: 278-82.
3. Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord. 2002; 17: 910-6.
4. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996; 46: 922-30.
5. Seppi K, Yekhlef F, Diem A, Luginger Wolf E, Mueller J, Tison F, et al. Progression of parkinsonism in multiple system atrophy. J Neurol. 2005; 252: 91-6.
6. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol. 2002; 9 Suppl 3: 23-30.
7. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003; 18: 467-86.
8. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1997; 62: 352-6.
9. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997; 12: 133-47.
10. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009; 132(Pt 1): 156-71.
11. 18 F-FDG PET. Eur J Radiol. 2004; 51: 223-33.
12. van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006; 47: 384-92.
13. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002; 58: 575-80.
14. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010; 51: 596-609.
15. 123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000; 15: 1158-67.
16. 123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001; 16: 1023-32.
17. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998; 39: 1521-30.
18. Kim JS. Practical Approach for the Clinal Use of Dopamine Transporter Imaging. Nucl Med Mol Imaging. 2008; 42(6): 425-34.
19. 18 F]FP-β-CIT and positron emmision tomography. J Cereb Blood Flow & Metabol. 2007; 27: 1397-406.
20. 18 F]FPCIT positron emission tomography. Ph. D. Thesis, Seoul National University, February 2006.
21. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981; 40: 2311-6.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of Idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Nerosurg Psychiatry. 1992; 55(3): 181-4.
23. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-6.
24. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998; 55: 969-78.
25. 18 F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007; 34: 345-51.
26. 18 F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease. Mov Disord. 2007; 22: 2352-8.
27. 18)F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci. 2012; 314: 111-9.
28. Kimura N, Hanaki S, Masuda T, Hanaoka T, Hazama Y, Okazaki T, et al. Brain perfusion differences in Parkinsonian disorders. Mov Disord. 2011; 26(14): 2530-7.
29. Sun FT, Schriber RA, Greenia JM, He J, Gitcho A, Jagust WJ. Automated template-based PET region of interest analyses in the aging brain. NeuroImage. 2007; 34: 608-17.
30. 123I-FP-CIT SPECT. Nucl Med Mol Imaging. 2009; 43: 10-8.
31. 123I-FP-CIT SPECT Study. Nucl Med Mol Imaging. 2007; 41: 272-9.
32. 18 F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995; 59: 597-600.
33. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001; 57: 2089-94.
34. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003; 24: 149-50.
35. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994; 14: 783-801.
36. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 1993; 115: 1-17.
37. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage. 2005; 26: 912-21.
38. 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging. 2003; 30: 16-24.
39. 2O PET imaging. BMC Nucl Med. 2006; 6: 4.
40. 11C-labeled Pittsburgh compound B. J Nucl Med. 2011; 52: 393-400.
41. Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997; 54: 937-44.